Core Recommendations for Equitable Digital Medicine Access

By HEOR Staff Writer

May 18, 2026

equitable digital medicine access

Ensuring equitable digital medicine access stands as a central goal of the Council of Europe’s latest guidance on remote pharmaceutical services. The CM/Rec(2026)7 recommendation requires that authorised pharmacies and non-pharmacy outlets maintain identical standards of safety, quality and continuity whether medicines are supplied in person or online, while closing regulatory gaps that risk distorting medicine use or public health.

Aligning Oversight Across Borders

There are several high-impact elements that directly affect health-system efficiency. Remote and online services must not create advantages for digital providers over physical ones, thereby avoiding market distortions in pricing, utilisation or reimbursement. Key safeguards include designated responsible persons at each outlet, prescription verification, risk assessments for high-risk medicines and compliance with both origin and destination country rules. These steps enable consistent research by keeping data on medicine use and patient outcomes comparable across channels.

Strengthening Legal and Technical Foundations

Building on the MEDICRIME Convention and prior resolutions on data protection, the recommendation outlines legislative reviews, regulatory capacity building and interoperable IT systems for secure exchange of electronic records and e-prescriptions. Member states are asked to map oversight gaps, compile harmonised lists of medicines suitable for remote supply and publish registers of authorised providers.

Protecting Value and Preventing Exclusion

These provisions promote equitable digital medicine access while reducing the chance of increased downstream costs from misuse or substandard products. Requirements for continuity of care, prescriber-pharmacist collaboration and safeguards against digital exclusion help sustain value-based pricing models that depend on reliable real-world evidence. Cross-border cooperation and platform accountability measures further stabilise supply chains and expenditure patterns.

Reference url

Recent Posts

mifepristone safety study
Mifepristone Safety Study: Ensuring Continued Regulatory Oversight

By João L. Carapinha

June 6, 2026

The mifepristone safety study launched by the FDA in April 2026 is actively collecting high-quality real-world data to determine whether the current Risk Evaluation and Mitigation Strategy (REMS) program still strikes the right balance between clinical benefits and potential harms. S...
HIV prevention access strategies
HIV Prevention Access Strategies Through Collaborative Partnerships in South Africa

By João L. Carapinha

June 6, 2026

HIV prevention access strategies have reached a pivotal moment in South Africa with the imminent launch of lenacapavir, a long-acting injectable administered twice yearly. This coordinated effort directly confronts the country’s immense HIV burden, including 7.8 million people living with the vir...
cancer productivity Asia-Pacific
Cancer Productivity Disparities in the Asia-Pacific Region

By João L. Carapinha

June 5, 2026

New research exposes a deepening divide in cancer productivity Asia-Pacific, where middle-income countries face rapidly escalating productivity losses from premature cancer deaths and disability, while high-income economies have begun to stabilise their burdens. Between 2010 and 2022, indirect ec...